FOXO Technologies Announces First Distribution Partner and Begins Product Rollout in California; Expands Executive Team With Insurance Industry Talent – Yahoo Finance
Recruits first distribution partner representing over 4,000 independent agents
FOXO LIFE to hold its first agent recruitment events in Southern California
James Grauel, Jr. appointed as Chief Distribution Officer of FOXO LIFE
MINNEAPOLIS, October 12, 2022–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE, recruited its first distribution partner, California-based BGA Insurance, to begin rolling out Life Insurance Designed to Keep You Alive™ to agents across the state. FOXO also announced the appointment of James Grauel, Jr. as Chief Distribution Officer ("CDO") of FOXO LIFE to spearhead the launch of longevity-focused life insurance products with independent agents.
FOXO LIFE is partnering with leading independent insurance agencies across the United States who share its vision and goal of modernizing the industry. Grauel joins the team with decades of experience working in the life insurance industry from both the carrier and independent agent distribution viewpoints. As CDO, Grauel will manage the development of FOXO LIFE’s network of independent agents selling longevity science-powered life insurance.
"I am thrilled to join a team that is building the most exciting thing I’ve seen in this industry over the course of my career," said Jim Grauel, Jr., Chief Distribution Officer of FOXO LIFE. "Creating more value for life insurance consumers by aligning their healthy longevity with the natural financial interest of life insurance carriers is an incredible and obvious innovation the industry needs."
FOXO LIFE will be holding its first agent distribution rollout events in Southern California with BGA Insurance, its first broker-general agent, who represents over 4,000 independent agents who are now able to sell life insurance products with FOXO LIFE’s Longevity Report.
"We are excited to work with FOXO LIFE to bring our agent base the opportunity to reframe the life insurance conversation from death protection, to life, health, and longevity," said Barry Zimmerman, President. "The real game changer will be when FOXO LIFE introduces saliva-based underwriting protocols to mitigate the need for blood and urine specimen collection."
FOXO LIFE’s first agent recruitment events will be held:
October 19th in Huntington Beach
November 1st in San Diego
November 2nd in Los Angeles, El Segundo
November 3rd in Sacramento, Roseville
For agents interested in attending an event – contact Alicia at sales@foxolife.com or 888.405.8957.
"We like to say that FOXO LIFE was created by agents, for agents," said Jon Sabes, Founder and CEO of FOXO. "This means that the products and services we are bringing to market are designed to address major industry pain points that fall most directly on agents. Making it easier and more exciting for agents to sell life insurance is our first order of business."
Today’s news comes four weeks after FOXO became a publicly traded company on the New York Stock Exchange American under the symbol "FOXO" via its merger with Delwinds Insurance Acquisition Corp ("Delwinds"), valuing the combined company at an estimated enterprise value of $369 million.
About FOXO Technologies Inc. ("FOXO")
FOXO is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance’s consumer value proposition with the FOXO Longevity Report™. For more information about FOXO, visit www.foxotechnologies.com. For more information about FOXO LIFE, visit www.foxolife.com. For investor information and updates, visit https://foxotechnologies.com/investors/.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended or an exemption therefrom.
Forward-Looking Statements
This press release contains certain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by management teams of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words "anticipate," "believe," "could," "expect," "estimate," "future," "intend," "strategy," "may," "might," "strategy," "opportunity," "plan," project," "possible," "potential," "project," "predict," "scales," "representative of," "valuation," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors, changes in laws and regulations affecting FOXO’s business, and changes in the combined capital structure, (ii) the ability to implement FOXO’s business plans, forecasts, and other expectations, (iii) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans, (iv) the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (v) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO’s prospective customers operate, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" filed with the SEC, and risks and uncertainties indicated in the Registration Statement, including those set forth under "Risk Factors" therein, and other documents filed or to be filed by FOXO from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005349/en/
Contacts
Contacts / Investor Relations
Cody Slach, Matthew Hausch
Gateway Investor Relations
(949) 574-3860
FOXO@gatewayir.com
Related Quotes
Hemp smokables company Hempacco Co Inc (NASDAQ: HPCO) reported a 486% year-on-year jump in first-half FY22 revenue to about $2.8 million. The company's collaboration with HBI-Raw, first launched in the fourth quarter of 2021, was a key revenue driver in the first half of the year. Hempacco listed its common shares on The Nasdaq Capital Market, effective August 30, 2022, under the symbol HPCO. Through IPO, it raised a total of $6 million of gross proceeds, offering 1 million shares at $6.00 per s
Energy inflation remains a serious concern. Protect your portfolio.
Shares of Moderna surged more than 11% on Wednesday after the biotech company [announced](https://investors.modernatx.com/news/news-details/2022/Merck-and-Moderna-Announce-Exercise-of-Option-by-Merck-for-Joint-Development-and-Commercialization-of-Investigational-Personalized-Cancer-Vaccine/default.aspx) it would develop and sell a personalized cancer vaccine with Merck. The stock was the biggest gainer on the S 500 around midday. Shares of Merck were little changed. Merck will pay Moderna $250 m
The Dow Jones Industrial Average ended a day of choppy trading with a 0.1% drop. The morning's 0.2% uptick faded early, but the index built momentum after the Fed's minutes release at 11 a.m. ET. The Fed's minutes on Wednesday showed that the path to higher interest rates remains intact.
The big question: Has the market hit a bottom yet? Well, according to Oppenheimer's Head of Technical Analysis Ari Wald, there are signs one is forming, the most notable of which is that the Russell 2000 index – the barometer for small-cap stocks – “held to the June lows in the most recent late Q3 move to the downside." Wald also notes that the signal of a market top is when the S&P 500 makes a “higher high, and small caps make a lower high," and we are currently seeing the opposite scenario pla
Altogether, the seasonally adjusted inflation still stood at 8.3% over the past 12 months in August. “High inflation is unlikely to become a permanent feature of the economy,” Aliaga-Diaz assured, adding that “central banks are trying hard to bring it down” though that “may cost them a mild recession.” Instead, Aliaga-Diaz says the best strategy is to look ahead “over medium and long-term horizons,” and that the “odds are that markets will be better than the last few months.”
Stocks were quiet Wednesday, as investors avoided rallying into the CPI inflation report. EV plays Albemarle and Aehr Test Systems dived.
Those hoping for the fourth quarter to herald a stock market comeback have been disappointed so far. A late-year rally has yet to properly materialize with the market still factoring further turmoil as the fight against inflation continues and the specter of a recession remains. However, while the prospect of a recession looms, Morgan Stanley’s Investment Management Managing Director Andrew Slimmon points out that many stocks already appear to be taking for granted the likelihood of a recession.
Analysts at Cowen Group and Morgan Stanley see significant upside for investors that own these Warren Buffett stocks.
(Bloomberg) — JPMorgan Chase & Co.’s boss Jamie Dimon says the US stock market could suffer another “easy 20%” drop, which would push the benchmark index below 3,000 — a level it hasn’t seen since the depths of the coronavirus pandemic. So what would another slide of that magnitude actually look like and which stocks would get hit hardest? For one thing, it would be painful for investors, with technology and so-called growth shares likely taking the brunt of the suffering, with their elevated
Seeing S&P 500 growth stocks implode is tough to watch, unless you're ready to spot a buy point.
It's looking like a rough day for stocks. Our call of the day is a look at the future and a billion-dollar industry and some stocks to play it, from Citigroup.
(Bloomberg) — The Biden administration’s new restrictions on doing business with China are sending shock waves through the global semiconductor industry, with chip-equipment makers girding for perhaps the most painful fallout. Most Read from BloombergIntel Is Planning Thousands of Job Cuts in Face of PC SlumpHere’s How Weird Things Are Getting in the Housing MarketPutin Says All Infrastructure at Risk After Nord Stream HitAlex Jones Must Pay $965 Million for His Sandy Hook LiesUS Core Inflation
Online gaming platform Roblox (NYSE: RBLX) is a hit with kid gamers, but with Wall Street — not so much. Roblox stock was shocked yesterday when Barclays bank initiated coverage with an underweight rating (i.e., sell), sending the shares down more than 6% at one point. Today, Roblox's ride higher continued, and as of 12:12 p.m. ET on Wednesday, the shares were up 5.7%.
Shares of Upstart Holdings (NASDAQ: UPST), an AI-powered lending platform, were rising today on seemingly no company-specific news. Instead, some investors may be looking at the company's recent share price declines and thinking that now is a good buying opportunity. Shares of Upstart have crashed over the past six months, falling 73% as investors have been worried about the Federal Reserve's aggressive interest rate hikes as it tries to tamp down inflation.
BofA analyst Vivek Arya maintained an Underperform on Intel Corp (NASDAQ: INTC) and a $30 price target. Two separate media reports suggested INTC’s plan to reduce its marketing and sales headcount by 20% and create greater decision-making separation between its design and manufacturing teams. Both steps were necessary but insufficient to change his fundamental concerns around core strategic, competitive and financial risks, Arya mentioned in his Wednesday note titled “First take on headcount red
Petrobras (PBR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
“After too many years of paying for oversight, I finally woke up to the reality that it cannot be in the investor’s best interest as long as the manager is rewarded for assets under management.” Well, firstly the AUM model — which stands for assets under management and is often a flat 1% of one’s assets — isn’t without controversy.
SQM (SQM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The world’s largest contract chip maker raised its revenue guidance earlier this year but the stock has sunk on macroeconomic headwinds.